We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Steven Madden (SHOO) in Q4 Earnings?
Read MoreHide Full Article
We expect Steven Madden, Ltd. (SHOO - Free Report) to report year-over-year declines in the top and bottom line when it releases fourth-quarter 2020 results on Feb 25, before market open. Although the Zacks Consensus Estimate for the quarter’s earnings has been stable in the past 30 days at 21 cents, it suggests a plunge of 46% from 39 cents earned a year ago. Moreover, the consensus estimate for quarterly revenues of $342.8 million suggests more than a 17% decrease from the prior-year quarter’s tally.
However, the fashion-forward footwear, apparel and accessories dealer has a trailing four-quarter earnings surprise of 18.4%, on average.
Key Factors to Note
Steven Madden has been struggling with a sluggish wholesale business for a while now, which might have hurt the company’s fourth-quarter performance. Lower wholesale footwear and accessories/apparel revenues have been marring the wholesale unit. Management at its third-quarter earnings call on Oct 27 stated that the wholesale business will continue to remain under pressure mainly owing to the adverse impacts of the pandemic. For the quarter under review, it anticipated a decline in high-teens percentage year over year for the division. However, it projected a sequential improvement for the division on continued recovery in its flagship brand, in both footwear and handbags.
The coronavirus pandemic has also hit Steven Madden’s Retail segment hard owing to a major decline in the brick-and-mortar business. Apparently, management projected sales decline in high-teens percentage on a year-over-year basis for the Retail business. Bleak fourth-quarter-revenue forecasts for both the segments might have taken a toll on the company’s top line.
However, the company’s e-commerce business has been a bright spot amid the pandemic. Robust gains from increased investment in digital marketing and solid consumer reception to capabilities such as ‘try before you buy’ have been contributing to the company’s performance. We note that the company’s actions, including enhancing digital initiatives, adjusting merchandise mix, and managing expense structure might have cushioned the quarter’s performance to some extent. Management at its last-earnings call had projected operating expense contraction of nearly 10% year over year for the fourth quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict a beat for Steven Madden this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Target (TGT - Free Report) has an Earnings ESP of +9.79% and a Zacks Rank #2.
American Outdoor BrandsAOUT has an Earnings ESP of +15.15% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
What's in the Cards for Steven Madden (SHOO) in Q4 Earnings?
We expect Steven Madden, Ltd. (SHOO - Free Report) to report year-over-year declines in the top and bottom line when it releases fourth-quarter 2020 results on Feb 25, before market open. Although the Zacks Consensus Estimate for the quarter’s earnings has been stable in the past 30 days at 21 cents, it suggests a plunge of 46% from 39 cents earned a year ago. Moreover, the consensus estimate for quarterly revenues of $342.8 million suggests more than a 17% decrease from the prior-year quarter’s tally.
However, the fashion-forward footwear, apparel and accessories dealer has a trailing four-quarter earnings surprise of 18.4%, on average.
Key Factors to Note
Steven Madden has been struggling with a sluggish wholesale business for a while now, which might have hurt the company’s fourth-quarter performance. Lower wholesale footwear and accessories/apparel revenues have been marring the wholesale unit. Management at its third-quarter earnings call on Oct 27 stated that the wholesale business will continue to remain under pressure mainly owing to the adverse impacts of the pandemic. For the quarter under review, it anticipated a decline in high-teens percentage year over year for the division. However, it projected a sequential improvement for the division on continued recovery in its flagship brand, in both footwear and handbags.
The coronavirus pandemic has also hit Steven Madden’s Retail segment hard owing to a major decline in the brick-and-mortar business. Apparently, management projected sales decline in high-teens percentage on a year-over-year basis for the Retail business. Bleak fourth-quarter-revenue forecasts for both the segments might have taken a toll on the company’s top line.
However, the company’s e-commerce business has been a bright spot amid the pandemic. Robust gains from increased investment in digital marketing and solid consumer reception to capabilities such as ‘try before you buy’ have been contributing to the company’s performance. We note that the company’s actions, including enhancing digital initiatives, adjusting merchandise mix, and managing expense structure might have cushioned the quarter’s performance to some extent. Management at its last-earnings call had projected operating expense contraction of nearly 10% year over year for the fourth quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict a beat for Steven Madden this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Steven Madden, Ltd. Price and EPS Surprise
Steven Madden, Ltd. price-eps-surprise | Steven Madden, Ltd. Quote
Although Steven Madden has a Zacks Rank #2, the company’s Earnings ESP of 0.00% makes surprise prediction difficult.
Stocks With Favorable Combinations
Here are a few companies you may want to consider, as our model shows that these have the right combination to post an earnings beat:
Camping World (CWH - Free Report) has an Earnings ESP of +45.46% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Target (TGT - Free Report) has an Earnings ESP of +9.79% and a Zacks Rank #2.
American Outdoor Brands AOUT has an Earnings ESP of +15.15% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>